LG Electronics Inc. has collaborated with sleep-tracking software startup, Asleep, to develop smart home appliances that utilize sleep analytics technology.
Under its memorandum of understanding with Asleep, LG will create a smart home appliance device that offers optimized services based on the customer’s sleeping status and patterns,
As long as a smartphone, smart TV, speaker, or other devices with a microphone is present, Asleep's artificial intelligence (AI)-based technology can measure different sleep phases.
For instance, if a customer is deemed sleeping, the air purifier in the bedroom switches to sleep mode automatically, and the air conditioner lowers the temperature to accommodate for the best air quality based on recent sleep records.
Asleep will display its products at the Consumer Electronics Show next month and hold demonstrations of a smart bedroom environment with LG’s premium home appliances and sleep analytics technology.


US, Japan Reaffirm Strong Currency Coordination Amid Yen Volatility
KOSPI Hits Record High as AI Chip Demand Boosts Samsung and SK Hynix
Morgan Stanley Bets on Optical Component Stocks in Greater China Tech Sector
Asian Stocks Rise Despite Middle East Tensions as Chipmakers Boost Markets
Palantir Reports Record Growth, Raises 2026 Revenue Outlook Above Expectations
RFK Jr. Faces Scrutiny Over David Geier’s HHS Role and Vaccine Review Work
AMD Q1 Earnings Surge on AI Demand, Stock Jumps After Strong Guidance
Dell Stock Hits Record High After Trump Endorsement, AI Server Demand Fuels Rally
CDC Acting Director Urges Measles Vaccination as U.S. Cases Surge in 2026
Broadcom Eyes $35 Billion AI Chip Financing Deal With Apollo and Blackstone
U.S.-China AI Talks May Take Center Stage at Trump-Xi Summit
Orsted Q1 EBITDA Beats Expectations Despite U.S. Impairments
OCBC Q1 Profit Rises 5% on Strong Wealth Management and Non-Interest Income
Kuaishou Stock Jumps on Kling AI IPO Plans and $20 Billion Valuation
Infineon Raises 2026 Outlook as AI Data Center Chip Demand Surges
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 



